He said Town Manager Reginald “Buzz” Stapczynski is eager to meet with company representatives.
“The town manager is hoping to talk to them about their business plan and what the town could do to work with them as a new corporate partner,” Materazzo said. “It’s great to see the building be reoccupied for this type of use.”
Sarepta plans to file by the end of the year for U.S. approval for a drug called Eteplirsen, which treats Duchenne muscular dystrophy. It is also working on developing an additional seven drugs that “target other genotypes,” which the spokesman called “follow-on drug candidates.” Duchenne muscular dystrophy affects 1 in 3,600 boys and causes rapid muscle degeneration and eventual death, according to the National Institutes of Health, or NIH. It is caused by a defective gene, but can occur in people with or without a known family history of the condition.
Baker said the property is being purchased for $15 million and the building will be retrofitted for an additional $10 million.